Metal Complex Formation and Anticancer Activity of Cu(I) and Cu(II) Complexes with Metformin.
Sherin AbdelrahmanMawadda AlghrablyMarcello CampagnaCharlotte Armgard Emma HauserMariusz JaremkoJoanna Izabela LachowiczPublished in: Molecules (Basel, Switzerland) (2021)
Metformin has been used for decades in millions of type 2 diabetes mellitus patients. In this time, correlations between metformin use and the occurrence of other disorders have been noted, as well as unpredictable metformin side effects. Diabetes is a significant cancer risk factor, but unexpectedly, metformin-treated diabetic patients have lower cancer incidence. Here, we show that metformin forms stable complexes with copper (II) ions. Both copper(I)/metformin and copper(II)/metformin complexes form adducts with glutathione, the main intracellular antioxidative peptide, found at high levels in cancer cells. Metformin reduces cell number and viability in SW1222 and K562 cells, as well as in K562-200 multidrug-resistant cells. Notably, the antiproliferative effect of metformin is enhanced in the presence of copper ions.
Keyphrases
- multidrug resistant
- type diabetes
- induced apoptosis
- risk factors
- end stage renal disease
- chronic kidney disease
- cardiovascular disease
- metabolic syndrome
- newly diagnosed
- squamous cell carcinoma
- single cell
- cell cycle arrest
- skeletal muscle
- oxidative stress
- ejection fraction
- squamous cell
- endoplasmic reticulum stress
- cell proliferation
- young adults
- prognostic factors
- reactive oxygen species
- patient reported outcomes
- oxide nanoparticles